Clinical Trial Update: Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial for very early FDG-PET/CT-response adapted therapy in advanced Hodgkin lymphoma was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Hodgkin Lymphoma | Phase 3 | Status: WITHDRAWN